Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present ...

Associate Professor of Art and Head of Digital Media at the University of Nevada, Reno, explores the relationship between ...

The transparency gap isn’t just anecdotal. Stanford’s Foundation Model Transparency Index initially scored leading developers ...

New research has charted the major developmental stages in the brain’s wiring—from early-life pruning to late-life network ...

Researchers have used metamathematical techniques to show that certain theorems that look superficially distinct are in fact ...